GlobalSurg-CovidSurg Week
GlobalSurg-CovidSurg Week: Determining the Optimal Timing for Surgery Following SARS-CoV-2 Infection
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
- Prospective, observational international cohort study.
- Any hospital worldwide can participate (including hospitals that have not admitted SARS-CoV-2 infected patients).
- All patients undergoing a surgical procedure in an operating theatre will be included. All consecutive eligible patients should be included.
- 7-day data collection period, with follow-up at 30 days after surgery for each patient. However, no changes should be made to normal patient care/ follow-up pathways
- Primary outcome is 30-day mortality.
- All collaborators will be included as PubMed-citable co-authors on resulting publications.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Aneel Bhangu, PhD
- Phone Number: +44 (0) 121 3718121
- Email: aneel.bhangu@gmail.com
Study Contact Backup
- Name: Dmitri Nepogodiev, Master
- Phone Number: +44 (0) 121 3718121
- Email: D.Nepogodiev@bham.ac.uk
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria
- Any operation (elective or emergency) done in an operating theatre by a surgeon.
- All surgical specialties including: acute care surgery, breast surgery, cardiac surgery, colorectal surgery, general surgery, gynaecology, hepatobiliary surgery, neurosurgery, obstetrics, oesophagogastric surgery, ophthalmology, oral and maxillofacial surgery, orthopaedics, otolaryngology, paediatric surgery, plastic surgery, thoracic surgery, transplant surgery, trauma surgery, urology, vascular surgery.
- Day case surgery and inpatient surgery included.
- Any SARS-CoV-2 status (positive at any time, negative, not tested).
- All ages including children and adults.
Exclusion criteria:
Minor procedures (full list will be available in the protocol).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative mortality
Time Frame: 30 days after surgery
|
Mortality at 30 days after surgery
|
30 days after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In-patient mortality
Time Frame: 30 days after surgery
|
Mortality while the patient is admitted to hospital
|
30 days after surgery
|
|
Post-operative pulmonary complications
Time Frame: 30 days after surgery
|
30-day postoperative pulmonary complications (pneumonia [CDC definition], ARDS, unexpected ventilation)
|
30 days after surgery
|
|
Post-operative venous thromboembolism
Time Frame: 30 days after surgery
|
30-day venous thromboembolism (deep vein thrombosis/ pulmonary embolism)
|
30 days after surgery
|
|
Post-operative complications
Time Frame: 30 days after surgery
|
30-day Clavien-Dindo grade
|
30 days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Glasbey J; COVIDSurg and GlobalSurg Collaboratives. Peri-operative outcomes of surgery in children with SARS-CoV-2 infection. Anaesthesia. 2022 Jan;77(1):108-109. doi: 10.1111/anae.15614. Epub 2021 Nov 5. No abstract available.
- Nepogodiev D; COVIDSurg and GlobalSurg Collaboratives. Timing of surgery following SARS-CoV-2 infection: country income analysis. Anaesthesia. 2022 Jan;77(1):111-112. doi: 10.1111/anae.15615. Epub 2021 Nov 5. No abstract available.
- Lobo D, Devys JM. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia. 2022 Jan;77(1):110. doi: 10.1111/anae.15540. Epub 2021 Jul 12. No abstract available.
- COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. Br J Surg. 2021 Sep 27;108(9):1056-1063. doi: 10.1093/bjs/znab101.
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GS-CSWeek.20200713
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
NCT04981769Not yet recruiting
-
NCT04885764Recruiting
-
NCT04608305Completed
-
NCT04864925Completed
-
NCT05045846Completed
-
NCT04973735Active, not recruiting
-
NCT04773756Completed